HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.02% | -12.17% | -11.56% | -15.48% | 1.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.02% | -12.17% | -11.56% | -15.48% | 1.20% |
| Cost of Revenue | 7.78% | 3.64% | 15.84% | 20.60% | 25.49% |
| Gross Profit | -5.24% | -16.66% | -18.23% | -22.91% | -4.84% |
| SG&A Expenses | 3.02% | -7.47% | -11.10% | -1.69% | -24.65% |
| Depreciation & Amortization | -22.89% | -32.89% | -30.00% | -28.85% | -18.93% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.64% | -16.33% | -14.79% | -11.15% | -14.22% |
| Operating Income | 72.88% | 38.14% | 32.45% | -8.89% | 73.07% |
| Income Before Tax | 44.84% | 33.06% | 82.77% | -5.20% | 18.36% |
| Income Tax Expenses | 13.33% | 86.08% | 3,383.76% | 27.50% | 178.95% |
| Earnings from Continuing Operations | 44.03% | 29.81% | 39.79% | -5.42% | 15.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.03% | 29.81% | 39.79% | -5.42% | 15.99% |
| EBIT | 72.88% | 38.14% | 32.45% | -8.89% | 73.07% |
| EBITDA | -13.38% | -29.76% | -28.63% | -52.26% | 31.23% |
| EPS Basic | -14.76% | 28.79% | 38.83% | -6.82% | 15.00% |
| Normalized Basic EPS | -22.42% | 6.43% | 7.90% | -6.57% | 23.66% |
| EPS Diluted | -19.54% | 28.79% | 38.31% | -6.22% | 14.94% |
| Normalized Diluted EPS | -22.42% | 6.43% | 7.90% | -6.57% | 23.66% |
| Average Basic Shares Outstanding | -4.85% | -1.42% | -1.59% | -1.31% | -1.16% |
| Average Diluted Shares Outstanding | -4.85% | -1.42% | -1.59% | -1.31% | -1.16% |
| Dividend Per Share | -- | -- | -- | -- | -95.32% |
| Payout Ratio | -- | -- | -- | -- | 1.00% |